Can I Take Omega-3 (EPA/DHA) with Farxiga (Dapagliflozin)?

The Short Answer: No Pharmacokinetic Interaction Exists

Dapagliflozin and omega-3 fatty acids do not compete for the same metabolic enzymes or transport proteins. Dapagliflozin is metabolized primarily via UGT1A9-mediated glucuronidation, with minor contributions from CYP3A4 [1]. Omega-3 fatty acids are absorbed through intestinal lymphatics, incorporated into phospholipids, and undergo beta-oxidation or eicosanoid synthesis rather than significant CYP or UGT metabolism [2]. Because the two agents travel entirely separate metabolic roads, neither raises nor lowers the plasma concentration of the other.

What "No Pharmacokinetic Interaction" Actually Means

A pharmacokinetic (PK) interaction would change how a drug is absorbed, distributed, metabolized, or excreted. None of those steps overlap here. The FDA label for dapagliflozin (Farxiga) lists metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, simvastatin, and warfarin as agents that were formally studied in dedicated PK trials, and omega-3 supplementation was not flagged as a concern in any of those studies [3].

Why This Distinction Matters Clinically

Patients sometimes confuse "no PK interaction" with "zero clinical consideration." That framing is incomplete. Two pharmacodynamic (PD) signals are worth tracking even when plasma levels stay predictable. PD interactions occur when two agents affect the same physiological endpoint independently, and both dapagliflozin and omega-3 fatty acids affect triglycerides and platelet function through separate but converging pathways.

How Dapagliflozin Affects Lipids and Platelets

Triglyceride Reduction with SGLT2 Inhibition

Dapagliflozin lowers fasting triglycerides modestly in patients with type 2 diabetes. In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin 10 mg daily reduced fasting triglycerides by approximately 9.6 mg/dL compared with placebo at a median follow-up of 4.2 years [4]. The proposed mechanism involves reduced hepatic de novo lipogenesis secondary to lower insulin levels and increased hepatic fatty acid oxidation driven by a mild ketogenic shift [5].

Platelet and Hemostatic Effects of SGLT2 Inhibitors

SGLT2 inhibitors modestly reduce platelet activation through reductions in oxidative stress and improvements in endothelial nitric oxide bioavailability [6]. These effects are small in magnitude but relevant when stacking additional antiplatelet supplements.

How Omega-3 Fatty Acids Affect Triglycerides and Platelets

Triglyceride Lowering: The Primary Indication

High-dose EPA/DHA is among the most potent non-statin therapies for hypertriglyceridemia. In the MARINE trial (N=229), icosapent ethyl 4 g/day reduced fasting triglycerides by 33.1% versus placebo in patients with triglycerides 500 to 2,000 mg/dL (P<0.0001) [7]. Even at the 2 g/day dose commonly used in dietary supplementation, triglyceride reductions of 15 to 20% are typical in patients with baseline hypertriglyceridemia [8].

The mechanism differs from dapagliflozin's. EPA and DHA suppress hepatic VLDL secretion, accelerate chylomicron clearance via lipoprotein lipase upregulation, and reduce the substrate available for triglyceride synthesis by inhibiting diacylglycerol acyltransferase [9].

Antiplatelet Effects of EPA/DHA

At doses above 3 g/day, EPA and DHA compete with arachidonic acid for cyclooxygenase, reducing thromboxane A2 synthesis and producing less potent thromboxane A3 instead [10]. The net effect is a reduction in ADP-induced platelet aggregation. The FDA has noted this effect and recommends caution when high-dose omega-3 products are combined with anticoagulants or antiplatelet drugs [11].

Standard dietary supplement doses of 1 to 2 g/day EPA/DHA produce clinically insignificant changes in platelet function in most adults. The threshold of concern rises when doses exceed 3 g/day, particularly in patients already on aspirin, clopidogrel, or warfarin.

The Additive Triglyceride-Lowering Interaction

When dapagliflozin and omega-3 fatty acids are used together, their independent triglyceride-lowering mechanisms stack. This is generally a wanted pharmacodynamic interaction for patients with hypertriglyceridemia, but it warrants tracking.

When Additive Lowering Is Beneficial

Patients with type 2 diabetes and concurrent hypertriglyceridemia (fasting TG >200 mg/dL) may achieve meaningful TG reductions by combining an SGLT2 inhibitor with high-dose omega-3. The 2023 American Diabetes Association Standards of Care state: "For patients with fasting triglyceride levels >135 mg/dL despite lifestyle therapy and statin treatment, prescription omega-3 fatty acids may be added to reduce cardiovascular risk" [12]. Dapagliflozin is independently recommended for cardiorenal risk reduction in the same guidelines.

When to Monitor More Closely

Patients whose baseline TG levels are already low (<100 mg/dL) face a theoretical risk of exaggerated lowering, though TG values below 50 mg/dL are rarely observed with these agents alone. A fasting lipid panel at baseline and every 3 to 6 months after adding either agent gives enough data to identify any unexpected response.

The Antiplatelet Consideration

The additive antiplatelet signal between dapagliflozin and omega-3 fatty acids is small and rarely clinically significant in patients not already on dedicated antiplatelet or anticoagulant therapy.

Risk Stratification by Omega-3 Dose

At 1 to 2 g/day EPA/DHA (the most common over-the-counter dosing), the platelet effect is minimal. Bruising or prolonged bleeding after minor cuts would be unusual at this dose in someone taking only dapagliflozin. At 3 to 4 g/day, the signal strengthens. Patients taking prescription icosapent ethyl (Vascepa 4 g/day) in the REDUCE-IT trial (N=8,179) had a higher rate of atrial fibrillation (5.3% vs. 3.9%, P<0.001) and peripheral edema compared with mineral oil placebo, though major adverse cardiovascular events fell by 25% relative risk [13].

Patients Who Should Flag This to Their Prescriber

• Anyone on warfarin, apixaban, rivaroxaban, dabigatran, or edoxaban
• Anyone on dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor)
• Anyone scheduled for surgery within 7 to 10 days
• Anyone with a personal or family history of a bleeding disorder

For these patients, the prescriber may ask them to hold high-dose omega-3 for 5 to 7 days before elective procedures, consistent with guidance from the American Heart Association [14].

Prescription Omega-3 vs. Over-the-Counter Fish Oil: A Critical Distinction

Not all omega-3 products are clinically equivalent, and this distinction matters when a patient is on Farxiga.

Icosapent Ethyl (Vascepa) vs. Mixed EPA/DHA Products

Icosapent ethyl (IPE) contains only EPA as the ethyl ester. The REDUCE-IT trial used IPE 4 g/day in statin-treated patients with established cardiovascular disease or diabetes plus one additional risk factor and TG 135 to 499 mg/dL. The result was a 25% relative risk reduction in the primary MACE endpoint (HR 0.75, 95% CI 0.68 to 0.83, P<0.001) [13]. Many Farxiga patients share exactly this risk profile, since dapagliflozin is indicated for T2DM and cardiovascular risk reduction.

Mixed EPA/DHA products (fish oil capsules, krill oil) add DHA alongside EPA. DHA may raise LDL-C slightly while still lowering TG [15]. In patients on dapagliflozin who are also trying to optimize their lipid panel, the choice between IPE-only and mixed EPA/DHA is worth a conversation with the prescriber.

Omega-3 Carboxylic Acids (Epanova)

Epanova (omega-3-carboxylic acids 4 g/day) was studied in the STRENGTH trial (N=13,078) against corn oil placebo in statin-treated patients with high cardiovascular risk. The trial was stopped early for futility after a median 3.1 years: the primary MACE endpoint did not differ significantly between arms (HR 0.99, 95% CI 0.90 to 1.09) [16]. This result separates the cardiovascular outcomes data clearly by product type and reinforces the importance of not treating all omega-3 products as interchangeable.

Dapagliflozin's Renal and Cardiac Indications: Does Omega-3 Change Anything?

Dapagliflozin carries three FDA-approved indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) with or without diabetes [3]. The interaction profile of omega-3 shifts subtly depending on which indication drives the Farxiga prescription.

In Type 2 Diabetes

The primary concerns are triglyceride management and glycemic stability. Omega-3 fatty acids do not affect blood glucose or HbA1c meaningfully at standard supplemental doses. A 2021 Cochrane review of 79 trials found that omega-3 supplementation produced a non-significant change in HbA1c (mean difference 0.07%, 95% CI -0.10 to 0.24%) in people with type 2 diabetes [17]. Dapagliflozin's glucose-lowering action is therefore unaffected.

In Heart Failure

Patients with HFrEF on dapagliflozin (supported by the DAPA-HF trial, N=4,744, which showed a 26% relative risk reduction in worsening HF or cardiovascular death) may also be on loop diuretics, beta-blockers, and ACE inhibitors or ARBs [18]. Omega-3 supplementation does not negatively interact with any of these drug classes pharmacokinetically. The antiplatelet caveat remains relevant if anticoagulation is also part of the regimen.

In Chronic Kidney Disease

In the DAPA-CKD trial (N=4,304), dapagliflozin reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, cardiovascular death, or renal death by 39% relative to placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [19]. CKD patients often have secondary hypertriglyceridemia driven by impaired lipoprotein lipase activity, making omega-3 supplementation a reasonable adjunct. No evidence suggests omega-3 worsens kidney function; a 2019 meta-analysis in the American Journal of Kidney Diseases (pooling 19 trials, N=1,426) found no significant effect of omega-3 on eGFR in CKD patients (mean difference 0.70 mL/min/1.73 m2, 95% CI -0.34 to 1.74) [20].

Practical Monitoring Framework for Patients Taking Both

Patients already taking dapagliflozin who want to add omega-3, or vice versa, can use the following clinical checkpoints.

Before Starting the Combination

• Confirm baseline fasting lipid panel (total cholesterol, LDL-C, HDL-C, TG)
• Review current anticoagulant or antiplatelet medications
• Note omega-3 dose and product type (OTC fish oil vs. Prescription IPE vs. Epanova)
• Confirm eGFR if CKD is the dapagliflozin indication

At 6 to 12 Weeks After Combining

• Repeat fasting lipid panel to verify expected TG reduction
• Ask about any new bruising, prolonged bleeding from minor cuts, or epistaxis
• No change to dapagliflozin dose is expected based on omega-3 addition

Annually

• Fasting lipid panel
• eGFR and urine albumin-to-creatinine ratio (standard dapagliflozin monitoring per ADA guidelines) [12]
• Review omega-3 dose and product; reassess cardiovascular risk category

The American Heart Association's 2021 Science Advisory states: "For patients with prevalent CVD, prescription n-3 FA can be considered as adjunctive lipid-lowering therapy, and the prescribing clinician should be aware of a potential increased risk of atrial fibrillation and bleeding" [14]. Patients on Farxiga for HFrEF or established cardiovascular disease fall squarely into this group and deserve that prescriber conversation before starting 4 g/day of any prescription omega-3 product.

What the FDA Label Says

The FDA-approved prescribing information for dapagliflozin (Farxiga) does not list omega-3 fatty acids, fish oil, EPA, or DHA in its drug interaction table [3]. The label specifically notes that dapagliflozin is not expected to be a clinically meaningful inhibitor or inducer of CYP enzymes, and it is not a substrate of P-glycoprotein efflux transporters in a way that would produce meaningful interactions with lipid supplements [3].

The FDA label for icosapent ethyl (Vascepa) cautions that drugs affecting coagulation should be used with caution at higher omega-3 doses [11]. This caution is directed primarily at anticoagulants and not at SGLT2 inhibitors specifically, but clinicians should read both labels together when managing a patient on both agents.

Common Mistakes to Avoid

Patients and clinicians sometimes make avoidable errors when managing this combination.

Assuming "natural" means no interaction: Omega-3 fatty acids at 4 g/day are pharmacologically active. The REDUCE-IT data treat them as a drug, not a supplement [13].

Overlooking the DHA/LDL effect: DHA can raise LDL-C by 3 to 5 mg/dL. In patients on dapagliflozin for CKD or HFrEF who are already optimizing lipids, switching from mixed EPA/DHA to EPA-only (icosapent ethyl) may produce a cleaner lipid profile [15].

Stopping omega-3 abruptly before surgery without telling the surgical team: Even modest antiplatelet effects from omega-3 should be disclosed to the anesthesiologist and surgeon.

Counting supplement omega-3 toward the REDUCE-IT dose of 4 g/day: Most OTC fish oil capsules contain 300 to 600 mg combined EPA/DHA per softgel. Reaching 4 g/day requires 7 to 13 standard softgels daily, a dose few patients take unsupervised.